On May 10, 2018, a vape cartridge customer filed a consumer class action in Los Angeles Superior Court against cannabis brand Brass Knuckles and Alvin Nathaniel Joiner, better known as the rapper Xzibit. Also named is SC Laboratories Inc. (SC Labs), the logo of which appears on the vape cartigage product's packaging.
Allegations of False Advertising, Misbranding and
Adulteration
The complaint alleges breach of warranty, false advertising, unfair
competition, misbranding and adulteration of Brass
Knuckles−branded THC (tetrahydrocannabinol) concentrate vape
cartridges as a result of alleged pesticide contamination and
inaccurate marketing statements regarding the product's THC
concentration. Specifically, the complaint states:
"Defendants prominently advertise and label the Products as being 'Lab Tested, Contaminant Free' ... when in fact they are contaminated by harmful pesticides. Defendants also prominently advertise and label the Products as being the 'Most Potent THC Cartridge Available.' However, the THC content of the Products is actually substantially lower than that of many competing vape cartridges. Defendants are able to charge substantially more for the Products than they would otherwise if consumers knew that the Products were contaminated with pesticides and not as potent as promised."
![](/images/article_images/703538a.jpg)
The complaint also is based on the allegation that the products were packaged with the following statement: "All our products are lab tested, ensuring that we deliver the Highest Quality Standards to our Patients. Verify yourself!" In addition, it is alleged that Xzibit also made various representations on social media, including on Instagram, such as: "Our oil is clean. Pls [sic] do your homework."
The plaintiff states that he retained the well-known cannabis testing lab Steep Hill to conduct laboratory tests on two flavors of the Brass Knuckles product, which revealed detectable amounts of pesticides, including bifenazate, etoxazole, myclobutanil, trifloxystrobin, permethrin, bifenthrin and carbaryl. The complaint alleges that the levels of contamination exceed the "Action Level" set forth for each of the observed residual pesticides by the California Code of Regulations, Title 16, Division 42, section 5719.
According to the complaint, the lab tests allegedly also revealed total cannabinoid potency between 59 percent and 77.3 percent for the products tested, but that many competing vape cartridges have substantially higher potencies, with tested results between 86 percent and 95 percent.
The Claimed Damages
Based on these allegations, the complaint asserts causes of action
for breach of express and implied warranties, negligent failure to
warn and violation of California's Unfair Competition Law (UCL,
codified at Business & Professions Code sections 17200 and
17500 et seq.) and California's Consumer Legal
Remedies Act (CLRA, codified at Civil Code section 1750).
Specifically, the plaintiff alleges that the defendants committed acts of unfair competition by engaging in false advertising and promotion of the products, likely to mislead consumers by misbranding the products and by selling adulterated products.
The alleged violations of the UCL and CLRA are particularly troublesome because, in addition to standard compensatory damages, the statutes allow – depending on proof and cause of action – for such remedies as injunctive relief, disgorgement of profits, restitution, attorney's fees and costs, and punitive damages. Those are precisely the damages that the plaintiff seeks, in addition to an injunction permanently enjoining the defendants from marketing the product as "contaminant free."
The Class to Be Certified
The complaint seeks to certify a class consisting of "All
persons or entities who purchased Brass Knuckles THC concentrate
vape cartridges from May 04, 2014, to the present that were
advertised, marketed, distributed and sold by Defendants." We
point out that − unlike in other types of consumer class
actions where the ability to ascertain the plaintiff class may be
difficult due to a lack of records and consumer identity −
this is less true for class actions involving cannabis due to
"track and trace" programs and other statutory
record-keeping requirements.
Analysis
Our team has predicted a coming wave of this type of cannabis
consumer class action based on allegations of false advertising and
unfair competition. As we discussed in earlier papers on the topic
(
New Rules for Cannabis: The Coming Wave of California False
Advertising and Unfair Competition Claims and
Marijuana Marketing: The Do's and Don'ts of Cannabis
Advertising in California ), these claims are premised
on violation of the state cannabis regulations, but are actionable
under state consumer protection laws. It is essential for every
California cannabis business to have a solid grasp of the cannabis
regulations and the unfair competition laws to fairly compete in
the new cannabis marketplace, and to avoid being named as an
unwitting defendant in an expensive and potentially company-ending
lawsuit.
Further complicating matters, insurance companies often decline coverage for these claims, leaving the company to fend for itself. As we have previously observed, this has proven disastrous for the dietary supplement industry over the past decade, with many companies forced to shut down after being found liable for uninsured damages and fees. History may be repeating itself with the cannabis industry. Although claims brought under the UCL and CLRA will be difficult to avoid as the California cannabis market expands, a well-informed licensee may nevertheless effectively mitigate its risk through vigilance and by instituting best practices consistent with the regulations.
This is one of the first – and certainly the most high-profile yet – of many more cannabis unfair competition cases to be filed. Stay tuned.
This article was previously printed in Cannabis Law Report.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.